Dr. Alok Kanojia (Dr. K)

And by the way, like, you know, when we say, oh, psychedelics are healthy for you and people are like swearing by them.

I don't think that most people understand this level of data, right?

This is when I prepared this video, this is just one of the papers that I looked through, right?

So you got to really be like informed y'all.

Like I know that people are talking about things on podcasts, but that's not the same as this.

So let's take a look.

So if you look at this, right, this shows a bigger improvement than this.

Does that make sense?

This shows a greater reduction in symptoms than these.

If it crosses the middle, by the way, that means that there's not a statistically significant result.

So it basically doesn't show a benefit.

So what this means is that if we do one measurement, so if we do a single post measurement, so here you are before the psychedelic, here you are after the psychedelic, we see larger effect sizes.

But the moment that we add a placebo, what happens to this curve, right?

So we start to see that things shift to the right.

The value of the treatment goes down the second that you add a placebo control.

So this is a really good example of people will say, like they'll look at this study and they'll see, oh my God, it leads to 50% improvements, but half of that could be placebo.

As we get to more sophisticated trials,

The value of psychedelics seems to be going down.

So this is LSD.

Here's MDMA.